--- title: Soluble Interleukin-6 Receptor (sIL-6R) description: Interleukin-6 (IL-6) is a multifunctional cytokine that regulates pleiotropic roles in immune regulation, inflammation, hematopoiesis, and oncogenesis. image: https://sbhsciences.com/hubfs/blog_sbh_author.jpg --- [![SBH Sciences](https://sbhsciences.com/hs-fs/hubfs/Imported%20sitepage%20images/sbhlogo.png?width=155&height=74&name=sbhlogo.png "SBH Sciences")](https://sbhsciences.com/) - Open submenu for ABOUT US - [ABOUT SBH](https://sbhsciences.com/about-sbh) - [LEADERSHIP](https://sbhsciences.com/sbh-leadership) - [CONTACT](https://sbhsciences.com/contact) - [CAREERS](https://sbhsciences.com/careers) - [SBH BIOVENTURE](https://sbhsciences.com/sbh-bioventure) - [SOLUTIONS](https://sbhsciences.com/services) Show submenu for SOLUTIONS - [CELL BASED ASSAYS](https://sbhsciences.com/cell-based-assay-services) - Open submenu for PRODUCT SERVICES - [PROTEINS](https://sbhsciences.com/protein-production-services) - [MOLECULAR BIOLOGY](https://sbhsciences.com/molecular-biology-services) - [CELL CULTURE](https://sbhsciences.com/cell-culture-services) - [ORGANOIDS](https://sbhsciences.com/blog/organoids-mini-organs-grown-for-research-and-drug-development) - [EXOSOMES](https://sbhsciences.com/exosome-services) - [BIOMARKER TESTING](https://sbhsciences.com/biomarker-testing) - Open submenu for DRUG DISCOVERY - [ADCC](https://sbhsciences.com/antibody-development-1) - [ELISA](https://sbhsciences.com/elisa-assays) - [BIOANALYTICAL](https://sbhsciences.com/bioanalytical-discovery-services) - [BIOSIMILARS](https://sbhsciences.com/biosimilars) - [CELL & GENE THERAPY](https://sbhsciences.com/cgt) - [SMALL MOLECULE](https://sbhsciences.com/small-molecule) - [FTE MODEL](https://sbhsciences.com/fte-model) - [CONSULTING](https://sbhsciences.com/mentoring) - Open submenu for INDICATIONS - [NEUROLOGY](https://sbhsciences.com/neurology) - [METABOLIC](https://sbhsciences.com/metabolic) - [ONCOLOGY](https://sbhsciences.com/oncology) - [KIDNEY](https://sbhsciences.com/kidney) - [MUSCLE](https://sbhsciences.com/muscle) - Open submenu for PRODUCTS - [CYTOKINES](https://sbhsciences.com/cytokines) - [MONOCLONAL ANTIBODIES](https://sbhsciences.com/monoclonal-antibodies) - [GLYCOBIOLOGY](https://sbhsciences.com/glycobiology) - Open submenu for INSIGHTS - [NEWS AND BLOG](https://sbhsciences.com/sbh-blog-and-news) - [REFERENCES AND PUBLICATIONS](https://sbhsciences.com/references) - [STRATEGIC PARTNERSHIPS](https://sbhsciences.com/partnerships) - Open submenu for ABOUT US - [ABOUT SBH](https://sbhsciences.com/about-sbh) - [LEADERSHIP](https://sbhsciences.com/sbh-leadership) - [CONTACT](https://sbhsciences.com/contact) - [CAREERS](https://sbhsciences.com/careers) - [SBH BIOVENTURE](https://sbhsciences.com/sbh-bioventure) - [SOLUTIONS](https://sbhsciences.com/services) Show submenu for SOLUTIONS - [CELL BASED ASSAYS](https://sbhsciences.com/cell-based-assay-services) - Open submenu for PRODUCT SERVICES - [PROTEINS](https://sbhsciences.com/protein-production-services) - [MOLECULAR BIOLOGY](https://sbhsciences.com/molecular-biology-services) - [CELL CULTURE](https://sbhsciences.com/cell-culture-services) - [ORGANOIDS](https://sbhsciences.com/blog/organoids-mini-organs-grown-for-research-and-drug-development) - [EXOSOMES](https://sbhsciences.com/exosome-services) - [BIOMARKER TESTING](https://sbhsciences.com/biomarker-testing) - Open submenu for DRUG DISCOVERY - [ADCC](https://sbhsciences.com/antibody-development-1) - [ELISA](https://sbhsciences.com/elisa-assays) - [BIOANALYTICAL](https://sbhsciences.com/bioanalytical-discovery-services) - [BIOSIMILARS](https://sbhsciences.com/biosimilars) - [CELL & GENE THERAPY](https://sbhsciences.com/cgt) - [SMALL MOLECULE](https://sbhsciences.com/small-molecule) - [FTE MODEL](https://sbhsciences.com/fte-model) - [CONSULTING](https://sbhsciences.com/mentoring) - Open submenu for INDICATIONS - [NEUROLOGY](https://sbhsciences.com/neurology) - [METABOLIC](https://sbhsciences.com/metabolic) - [ONCOLOGY](https://sbhsciences.com/oncology) - [KIDNEY](https://sbhsciences.com/kidney) - [MUSCLE](https://sbhsciences.com/muscle) - Open submenu for PRODUCTS - [CYTOKINES](https://sbhsciences.com/cytokines) - [MONOCLONAL ANTIBODIES](https://sbhsciences.com/monoclonal-antibodies) - [GLYCOBIOLOGY](https://sbhsciences.com/glycobiology) - Open submenu for INSIGHTS - [NEWS AND BLOG](https://sbhsciences.com/sbh-blog-and-news) - [REFERENCES AND PUBLICATIONS](https://sbhsciences.com/references) - [STRATEGIC PARTNERSHIPS](https://sbhsciences.com/partnerships) Search Search Search Search ![Soluble Interleukin-6 Receptor (sIL-6R)](https://sbhsciences.com/hubfs/blog_sbh_author.jpg) # *Apr 4, 2023 |* Soluble Interleukin-6 Receptor (sIL-6R) Interleukin-6 (IL-6) is a multifunctional cytokine that regulates pleiotropic roles in immune regulation, inflammation, hematopoiesis, and oncogenesis. ## *Share* - [mailto:?&subject=Soluble%20Interleukin-6%20Receptor%20(sIL-6R)&body=Soluble%20Interleukin-6%20Receptor%20(sIL-6R)%0A(https%3A%2F%2Fsbhsciences.com%2Fblog%2Fsoluble-interleukin-6-receptor-sil-6r)](mailto:?&subject=Soluble%20Interleukin-6%20Receptor%20(sIL-6R)&body=Soluble%20Interleukin-6%20Receptor%20(sIL-6R)%0A(https%3A%2F%2Fsbhsciences.com%2Fblog%2Fsoluble-interleukin-6-receptor-sil-6r)) - - - Soluble Interleukin-6 receptor (sIL-6R) **Scientific background** Interleukin-6 (IL-6) is a multifunctional cytokine that regulates pleiotropic roles in immune regulation, inflammation, hematopoiesis, and oncogenesis. Its biological activities are shared by IL-6-family of cytokines such as leukemia inhibitory factor and oncostatin M. IL-6 exerts its biological activities through interaction with specific receptors expressed on the surface of target cells. The receptor complex mediating the biological activities consists of two distinct membrane-bound glycoproteins: - IL-6 Receptor (IL-6R, gp80) is 80 kDa alpha subunit, transmembrane glycoprotein that is 449 aa long. It binds IL-6 with low affinity (Kd= 5.5 nM) - A signal-transducing non-ligand binding 130 kDa component (gp130) that is required for high-affinity binding complex (Kd = 50 pM) Upon binding of IL-6 to the receptor (alpha subunit), gp130 is homodimerized and is subsequently involved in down-stream signal processes binding tyrosine kinases and activating STAT1 and STAT3 transcriptional factors. Both IL-6R and gp130 also occur in soluble form in biological fluids and has been purified from human serum and urine. The number of cell types expressing IL-6 R does not reflect the spectrum of cell types that can respond to IL-6. Cells known to express IL-6 R include CD4+ and CD8+ T cells, hepatocytes, CD34+ stem cells neurons, neutrophils, monocytes and osteoblasts. **Soluble IL-6 Receptor** Soluble IL-6 receptor (sIL-6R) is a 50-55 kDa ligand binding protein, derived from the extracellular part of the gp80 receptor by either proteolytic cleavage of their membrane moiety (PC-sIL-6R; isoform 1) or by alternative splicing (DS-sIL-6R). The soluble form of IL-6R can bind its ligand and induce cellular responses by association with gp130, thus acting as an IL-6 agonist. Interestingly, the association of IL-6 with the soluble form of IL-6R alpha is capable of eliciting a biological response in cells that express only the membrane gp130. This type of activation, called "trans-signalling", renders virtually all cells capable of responding to IL-6/sIL-6R alpha complexes, making for a large new spectrum of IL-6 activities, ranging from the control of the immune response to involvement in pathological states. **Soluble interleukin-6 receptor as a prognostic factor in numerous clinical disorders:** In healthy individuals, blood levels of sIL-6R are in the range of 75-80 ng/mL, with elevated levels in myeloma (130-190 ng/mL) and HIV-infected patients (170 ng/mL). Elevated IL-6 concentrations have been reported in numerous clinical disorders (Jones S. A. et al, 2001, The *FASEB J. 15:43-58*), where they appear to orchestrate a variety of inflammatory responses. Given the agonistic properties of sIL-6R, it is evident that control of many of these IL-6-mediated events is regulated via sIL-6R. Consequently, when considering the role of IL-6 in disease progression, it is equally important to consider how sIL-6R affects its function. Although enhanced sIL-6R levels have been documented in a variety of disease states, we are only now beginning to appreciate the potential contribution sIL-6R may have in these pathologies. As a result, future studies must address this issue if the functional properties of IL-6 are to be fully understood. Initial clinical studies indicate the levels of sIL-6R, the alpha subunit, in the serum of patients with various diseases as summarized in table1. **Table 1. Soluble IL-6R level in disease**   | ***Clinical condition*** | ***sIL-6R*** | ***Soluble IL-6R levels (Alpha subunit)*** | ***Reference*** | | --- | --- | --- | --- | | **Cancers** | | | | | Breast cancer | ![](https://www.sbhsciences.com/grfx/arrowd.gif?width=15&height=11&name=arrowd.gif) | Serum sIL-6R levels were lower than in normal individuals | Jablonska, E. *Cytokine* 10,540-543, 1998 | | Pancreatic cancer | **![](https://www.sbhsciences.com/grfx/arrowd.gif?width=15&height=11&name=arrowd.gif)** | Soluble IL-6R levels unaltered from normal individuals | Barber, M. D. et al, *Clin. Sci.* 96,83-87, 1999 | | Multiple myeloma | **![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif)![](https://www.sbhsciences.com/grfx/arrowd.gif?width=15&height=11&name=arrowd.gif)** | The concentrations of sIL-6R were significantly higher in the patients who died within 3 years compared with those who survived. | Pulkki, K. et al, Cytokine. 16(3): 79-86, 2001 | | **Inflammatory disorders** | | | | | Rheumatoid arthritis | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | Elevated sIL-6R levels in the sera of patients were higher than those of the control group. | Polgar A et al, Med Sci Monit. 6(1): 13-8, 2000 | | Juvenile chronic arthritis | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | Significant increases in both IL-6 and sIL-6R, which correlated with fever | Keul R et al Cytokine.10 (9): 729-34, 1998 | | Osteoarthritis | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | Elevated levels, but not to the extent associated with rheumatoid arthritis | Kotake S et al, J Bone Miner Res. 11(1): 88-95,1996 | | Asthma | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | Asthmatic patients have high serum sIL-6R levels | Yokoyama A et al, Am. J. Respir. Crit. Care Med., 156 (5), 1688-1691, 1997 | | Crohn's disease | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | Increased levels of IL-6 and sIL-6R have been demonstrated in both serum and intestinal tissues of the patients | Ito H. Curr Drug Targets Inflamm Allergy. 2(2): 125-30, 2003 | | Interstitial lung disease | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | Raised sIL-6R levels contribute to systemic and local responses in pneumonia and sarcoidosis patients | Yokoyama A et al, Clin Exp Immunol.100 (2): 325-9, 1995 | | Inflammatory bowel disease | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | Elevated IL-6 and sIL-6R levels contribute to the pathogenesis of chronic intestinal inflammation | Atreya R et al, Nat Med. 6(5): 583-8, 2000 | | Systemic sclerosis | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | sIL-6R levels correlate with the severity of pulmonary fibrosis associated with systemic sclerosis | Hasegawa M et al,  *Rheumatology* 38,612-617, 1999 | | Intraocular inflammation | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | Elevated sIL-6R and IL-6 levels in the aqueous humor of uveitis patients | Petrinovic-Doresic, J. et al, Ocular* Immunol. Inflamm.* 7,75-84, 1999 | | Graves’ disease | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | An increased was observed in the serum concentration of sIL-6R in the course of Graves’ disease. | Bossowski A et al, J Pediatr Endocrinol Metab. 14,741-7, 2001 | | Endometriosis | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | Peritoneal and serum sIL-6R levels significantly higher than in other benign gynecologic conditions | Schroder, W. et al,* Clin. Exp. Obstet. Gynecol.* 23,10-14, 1996 | | **Neurological conditions** | | | | | Depression | ![](https://www.sbhsciences.com/grfx/arrowd.gif?width=15&height=11&name=arrowd.gif) | Significantly decreased sIL-6R and IL-6 concentrations in CSF compared with healthy subjects | Stubner, S et al, *Neurosci. Lett**.***259,145-148, 1999 | | Multiple sclerosis | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | Elevated serum sIL-6R concentrations correlate with disease severity | Padberg, F. et al, J*. Neuroimmunol**.***99,218-223, 1999 | | Schizophrenia and mania | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | Higher sIL-6R levels in psychotic patients than healthy volunteers | Maes, M. et al, J*. Psych. Res.* 29,141-151, 1995 | | Psychological stress | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | Elevated in post-traumatic stress disorder, especially in patients with major depression | Maes, M et al, *Biol. Psych.* 45,833-839, 1999 | | **Pathogen infections** | | | | | HIV | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | Viral infection promotes sIL-6R release | Honda, M. et al J*. Immunol**.***148,2175-2180, 1992 | | Urinary tract infection | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | Increased serum sIL-6R concentrations correlate with a loss of glomerular filtration rate | Jacobsen, S. H et al Nephron 80,401-407, 1998 | | Cerebral malaria | ![](https://www.sbhsciences.com/grfx/arrowu.gif?width=15&height=11&name=arrowu.gif) | Elevated IL-6 and sIL-6R levels after *P. falciparum* infection | Jakobsen, P et al Infect*. Immun.* 62,4374-4379, 1994 | SBH Sciences construct of sIL-6R is expressed as the isoform 1 that doesn't have the COOH-terminal tail (GSRRRGSCGL). SBH Sciences recombinant human soluble IL-6 receptor alpha, purified from mammalian 293 cells, is fully biologically active. Its activity is measured by its ability to increase IL-6 activity (growth inhibition of murine M1 cells). **Collaboration Opportunity** SBH Sciences is looking for partners to investigate SBH Sciences fully functional soluble IL-6 receptor as therapeutic agent as well as diagnostic tool. We are open for suggestions and would be [pleased to hear from you](https://sbhsciences.com/contact). ![SBH Blogger](https://sbhsciences.com/hs-fs/hubfs/blog_sbh_author.jpg?width=70&name=blog_sbh_author.jpg) ### Written By: SBH Blogger ### Sign up for our newsletter! **Discovery Research Products & Services** (508) 650-6218 | [Inquiries@SBHsciences.com](mailto:Inquiries@SBHsciences.com) The World's Leading Provider of Cytokine Cell-Based Assays Recombinant Cytokines, Enzymes, Antibodies, Cell-Based Assay and Innovative Process Development Solutions **[COMPANY](https://sbhsciences.com/about-sbh)** [About Us](https://sbhsciences.com/about-sbh) [SBH Leadership](https://sbhsciences.com/sbh-leadership) [Company Presentation](https://sbhsciences.com/hubfs/43587181/SBH_Presentation.pdf) [Strategic Partnerships](https://sbhsciences.com/partnerships) [References and Publications](https://sbhsciences.com/references) [News and Blog](https://sbhsciences.com/sbh-blog-and-news) [Careers](https://sbhsciences.com/careers) [Request a Quote](https://sbhsciences.com/contact) [Contact Us](https://sbhsciences.com/contact) **[SERVICES](https://sbhsciences.com/services)** [Automated Western Blot](https://sbhsciences.com/platform-technologies#wb) [Bioanalytical](https://sbhsciences.com/bioanalytical-discovery-services) [Biomarker Testing](https://sbhsciences.com/biomarker-testing) [Cell-Based Assay](https://sbhsciences.com/cell-based-assay-services) [Cell Culture Services](https://sbhsciences.com/cell-culture-services) [Cell & Gene Therapy (CGT)](https://sbhsciences.com/cgt) [Small Molecule](https://sbhsciences.com/small-molecule) [Biosimilars](https://sbhsciences.com/biosimilars) [Antibody Development](https://sbhsciences.com/antibody-development-1) [ELISA Services](https://sbhsciences.com/elisa-assays) [Molecular Biology](https://sbhsciences.com/molecular-biology-services) [Organoids](https://sbhsciences.com/blog/organoids-mini-organs-grown-for-research-and-drug-development) [Exosomes](https://sbhsciences.com/exosome-services) [Protein Purification/Production](https://sbhsciences.com/protein-production-services) [FTE Scientist Model](https://sbhsciences.com/fte-model) [Consulting](https://sbhsciences.com/mentoring) **INDICATIONS** [Oncology](https://sbhsciences.com/oncology) [Kidney](https://sbhsciences.com/kidney) [Muscle](https://sbhsciences.com/muscle) [Metabolic](https://sbhsciences.com/metabolic) [Neurology](https://sbhsciences.com/neurology) **[PRODUCTS](https://sbhsciences.com/products)** [Request a Quote](https://sbhsciences.com/contact) [Cytokines](https://sbhsciences.com/cytokines) [Monoclonal Antibodies](https://sbhsciences.com/monoclonal-antibodies) [Glycobiology](https://sbhsciences.com/glycobiology) **[SBH Bioventure](https://sbhsciences.com/sbh-bioventure)** [**SBH Diagnostics**](https://sbhdiagnostics.com/#)   [![linkedin](https://sbhsciences.com/hs-fs/hubfs/Imported%20sitepage%20images/linkedin.gif?width=45&height=44&name=linkedin.gif)](https://www.linkedin.com/company/sbh-sciences)     ©2026 SBH Sciences. All rights reserved. [Terms of Use](https://sbhsciences.com/tou) | [Privacy Policy](https://sbhsciences.com/tou#pp) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "SBH Blogger", "url" : "https://sbhsciences.com/blog/author/sbh-sciences" }, "dateModified" : "2026-01-20T21:37:16.009Z", "datePublished" : "2023-04-04T18:00:00.000Z", "headline" : "Soluble Interleukin-6 Receptor (sIL-6R)", "image" : [ "https://sbhsciences.com/hubfs/blog_sbh_author.jpg" ], "mainEntityOfPage" : { "@id" : "https://sbhsciences.com/blog/soluble-interleukin-6-receptor-sil-6r", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://sbhsciences.com/hubfs/Imported%20sitepage%20images/sbhlogo.png" }, "name" : "SBH Sciences" } } ``` ```json { "@context" : "https://schema.org", "@id" : "https://sbhsciences.com/blog/author/sbh-sciences#author", "@type" : "Person", "email" : "Inquiries@SBHsciences.com", "image" : { "@id" : "https://sbhsciences.com/blog/author/sbh-sciences#authoravatar", "@type" : "ImageObject", "url" : "https://43587181.fs1.hubspotusercontent-na1.net/hubfs/43587181/blog_sbh_author.jpg" }, "name" : "SBH Blogger", "sameAs" : [ ] } ``` ```json { "@context" : "https://schema.org", "@id" : "https://sbhsciences.com/blog/soluble-interleukin-6-receptor-sil-6r#blogposting", "@type" : "BlogPosting", "author" : { "@id" : "https://sbhsciences.com/blog/author/sbh-sciences#author" }, "commentCount" : 0, "dateModified" : "2024-10-01T12:0000+0000", "datePublished" : "2023-04-04T18:0000+0000", "headline" : "Soluble Interleukin-6 Receptor (sIL-6R)", "image" : "https://sbhsciences.com/blog/soluble-interleukin-6-receptor-sil-6r", "inLanguage" : "en", "keywords" : [ ], "mainEntityOfPage" : "https://sbhsciences.com/blog/soluble-interleukin-6-receptor-sil-6r", "name" : "Soluble Interleukin-6 Receptor (sIL-6R)", "publisher" : { "@id" : "https://www.yourdomain.com#organization" }, "url" : "https://sbhsciences.com/blog/soluble-interleukin-6-receptor-sil-6r", "wordCount" : 1240 } ```